AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: activity

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

Senate Endorses State AI Regulations—Impact Analysis on Tech Sector Algorithms

The recent Senate decision to reject an amendment that sought to impose a decade-long moratorium on state-level AI regulation underscores a pivotal moment for...

BBVA Deepens Partnership with Google Cloud to Innovate with AI

BBVA is taking a strategic step in its digital transformation by expanding its long-standing collaboration with Google Cloud through the deployment of Google...

PXPay Plus Teams Up with foodpanda to Launch Taiwan’s First Integration of Electronic Payment and Food Delivery

A New Delivery Payment Ecosystem for All Ages and Scenarios — Enjoy Up to 10% Rewards for the Launch! TAIPEI, July 1, 2025 /PRNewswire/ --...

VdoCipher’s Piracy Detection Engine Blocks 250,000+ Video Piracy Attempts in 12 Months

GURUGRAM, India, July 2, 2025 /PRNewswire/ -- In today's digital world, protecting premium video content is more critical than ever. While streaming has unlocked...

Lightchain AI Announces Final Token Distribution Round Prior to Mainnet Activation

SHREWSBURY, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, the AI-native blockchain infrastructure platform, has entered its Bonus Round after successfully completing 15 presale stages and raising more than $21.1 million from early supporters. The Bonus Round is now live at a fixed token price of $0.007125, marking the final opportunity for contributors to access Lightchain AI tokens before the mainnet launch scheduled for July 2025.

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

EZGO ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED MARCH 31, 2025

CHANGZHOU, China, July 1, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions...

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsActivity